Indication

Hyperlipidemia

Hyperlipidemia is a metabolic disorder characterized by abnormally elevated systemic concentrations of lipids or lipoproteins, including low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides. Read more about Hyperlipidemia

384 drugs 151 manufacturers

Advertisement

Drugs that treat it

Common Hyperlipidemia therapies.

Showing 316–324 of 384 drugs

PRAVASTATIN SODIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
DENTON PHARMA I

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
DENTON PHARMA I

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
APHENA PHARMA S

LOVASTATIN

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+7
APHENA PHARMA S

PRAVASTATIN SODIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
APHENA PHARMA S

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
APHENA PHARMA S

SIMVASTATIN

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+13
APHENA PHARMA S

NIACIN

NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
REDMONT PHARMAC

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
NOVADOZ PHARMAC
Filter & compare in the drug finder →Opens the drug finder with Hyperlipidemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hyperlipidemia.

Hyperlipidemia is a metabolic disorder characterized by abnormally elevated systemic concentrations of lipids or lipoproteins, including low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides.

Primarily impacting the cardiovascular and vascular systems across pediatric and adult populations, the condition stems from primary genetic mutations or secondary factors such as obesity, diabetes, and dietary intake.

Pathophysiologically, altered lipid synthesis, transport, or clearance leads to the accumulation of atherogenic circulating particles that deposit within the vascular endothelium.

This process accelerates systemic atherogenesis, substantially elevating the long-term clinical risk for coronary artery disease, myocardial infarction, and ischemic stroke.

Personalize your experience

Follow Hyperlipidemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it